| Details: |
Complex disease conditions are characterized by multifactorial etiologies and comorbidities often adds to the risk of complexities, further complicating diagnosis and treatment. Many of these conditions lack well-defined diagnostic markers or phenotypic features, making the identification of specific drug targets highly challenging. In such cases, treatment often relies on empirical, trial-and-error approaches rather than precise therapeutic strategies.
Over the past two decades, a parallel rise in the incidence of rare diseases has been observed, potentially linked to the widespread and sometimes arbitrary use of medications in complex conditions. The lack of precision in diagnosis, uncertainty in drug target identification, and variability in dosing practices may collectively contribute to adverse outcomes, including the emergence or exacerbation of rare disease phenotypes.
While pharmacogenetics has improved our understanding of individual variations in drug response, it addresses only part of the problem. Incorporating pharmaco-epigenetics—a field that examines how drugs influence gene expression through epigenetic mechanisms—offers a promising avenue for improving drug safety and efficacy in these complex scenarios. In this presentation, I will present evidences on how the medications in complex conditions can present rare conditions. The study is based on the use of antiseizure medications and antihypertensive medications and investigating their impact through a multi-omics framework, by integrating genomic, epigenomic, and proteomic resulting in some of the rare disease conditions. This systems-level approach aims to shed light on the unintended |